Key Highlights
- GSK to buy Nuvalent in a $10.6 billion all-cash transaction valued at $124 per share
- Shareholders receiving a 40% premium compared to Monday’s market close
- Shares of Nuvalent surged 39% to $122.90 during Tuesday’s opening session
- Acquisition brings GSK three non-small cell lung cancer therapies, with two pending FDA approval decisions in 2026
- GSK’s biggest acquisition since 2014
British pharmaceutical giant GSK revealed plans Tuesday to purchase Nuvalent, a Boston-based oncology biotech, in a $10.6 billion cash transaction, propelling Nuvalent shares up 39% to $122.90.
The $124-per-share purchase price delivers a substantial 40% premium over Nuvalent’s closing value on Monday. Meanwhile, GSK’s American depositary receipts held steady at $50.65, though the company’s London shares fell over 3%.
This transaction represents GSK’s most significant acquisition in more than ten years and signals a dramatic strategic realignment for the pharmaceutical powerhouse.
The deal brings GSK a trio of non-small cell lung cancer pipeline candidates. The most advanced programs are zidesamtinib, designed for ROS1-mutated tumors, and neladalkib, which inhibits ALK.
Both therapies have reached late-stage clinical development and are currently undergoing FDA evaluation. The regulatory agency is scheduled to issue decisions on September 18 and November 27, 2026, for the respective candidates.
A third investigational therapy, NVL-330, targets HER2 and remains in early phase I testing.
“These two leading candidates represent potentially best-in-class therapies that could reach the market this year pending FDA approval,” stated GSK CEO Luke Miels.
GSK Returns to Cancer Drug Development
GSK exited oncology more than a decade ago when it exchanged its cancer business with Novartis for their vaccines portfolio in 2014. This acquisition signals a definitive re-entry into cancer therapeutics as a strategic priority.
Miels, who assumed the CEO role in early 2026, had previously indicated to shareholders a preference for acquisitions in the £2 billion to £4 billion range. He defended the higher valuation by noting the deal essentially secures three separate products in one transaction.
After accounting for Nuvalent’s cash holdings, GSK’s net outlay totals approximately $9.4 billion. Financing will come through a combination of new debt arrangements, existing credit facilities, and available cash, with GSK maintaining its current credit rating.
Financial Implications for GSK
GSK confirmed its 2026 full-year financial projections remain intact. The pharmaceutical company anticipates the acquisition will begin contributing to revenue and core operating profit starting in 2027, with core earnings per share accretion materializing by 2029.
GSK noted the acquisition will help offset core operating profit during the exclusivity loss period for dolutegravir, which extends from 2028 through 2030.
The transaction is positioned to fast-track GSK’s presence in lung cancer treatment and establish a foundation for broader expansion complementing Ris-Rez, its B7-H3 antibody-drug conjugate now advancing through phase III trials.
Pending regulatory clearances, including Hart-Scott-Rodino antitrust approval, both parties anticipate completing the transaction by the end of Q3 2026.
The FDA’s verdict on Nuvalent’s two flagship therapies will arrive on September 18 and November 27, 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
